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Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant
women with CMVSir,
It is well known that cytomegalovirus (CMV) coinfection affects a
large proportion of peoplewithHIV,with a significant impact on dis-
ease progression and survival [1]. In HIV-CMV coinfected pregnant
women, however, few studies have been conducted: maternal
immunosuppression has been linked to a higher risk of CMV infant
infection, and CMVDNAaemia to highermaternal and infantmortal-
ity [2,3]. Overall, little is known about pregnancy outcomes and CMV
viraemia in CMV-coinfected pregnant women with HIV. To further
explore this issue, the impact of CMV coinfection was evaluated on
pregnancy outcomes in a national cohort of pregnant women with
HIV, assessing in a study subsample the prevalence and correlates
of CMV DNAaemia in HIV-CMV coinfected pregnant women.
Data from the Italian National Program on Surveillance on Anti-
retroviral Treatment in Pregnancy were used [4], considering all
HIV-infected women with known CMV serostatus. The main preg-
nancy outcomes were compared between women with and
without positive serology for CMV, and plasma CMV-DNA levels
were evaluated in a subset of CMV-positive women who had given
specific consent to virological evaluations and had evaluable
plasma samples. The cases were analysed retrospectively, and no
systematic screening for CMV infection was conducted in infants.
Ethics approval was obtained from the ethics committee of the
I.N.M.I. Lazzaro Spallanzani in Rome; ref. deliberations: 578/2001
(28 September 2001) and 7/2003 (26 February 2003). Plasma
CMV-DNA was quantified with the kPCR PLX Cytomegalovirus
DNA assay (Siemens Healthcare) using the VERSANT kPCR Molecu-
lar System (Siemens), with a detection limit of 214.6 (2.33 log) IU/
mL. Quantitative data were compared by the Mann-Whitney U test
and proportions by the chi-square test, with OR and 95% CI calcu-
lated. A p-value below 0.05 was considered to be significant, using
for all analyses the SPSS software, version 22.0 (IBM Corp, Released
2013, Armonk, NY, USA).
As of 21March 2016, among 2250 pregnancies with available in-
formation on CMV serostatus (62% of all cases in the database,
including ongoing pregnancies and cases lost to follow-up), 1490
were CMV antibody-positive (66.2%). Women with and without
positive serology for CMV were similar for age, CD4 counts, CDC-
HIV disease stage, parity, antiretroviral treatment experience, and
treatment status at conception. No differences between the two
groups were found for the main pregnancy outcomes, represented
by miscarriage or fetal demise, preterm delivery, low (<2500g) or
very low (<1500g) birthweight, intrauterine growth restriction
(gender- and gestational age-adjusted Z-score for birthweight
<10 percentile), major birth defects, delivery complications, andhttp://dx.doi.org/10.1016/j.cmi.2016.06.017
1198-743X/© 2016 European Society of Clinical Microbiology and Infectious Diseases. PuHIV transmission (Table 1). Among 1126 infants from CMV-
positivemothers with available information on clinical status, three
neonatal cases of CMV infection were reported.
Among the 1490 women positive for CMV antibodies, 123 (8.3%)
had available plasma samples collected during pregnancy, usually
(90.2%) after the first trimester, which were evaluated for CMV-
DNA quantitation. None of these women had clinical signs of new
viral infection or viral reactivation during pregnancy. Only four of
them (3.3%) had positive CMV DNAaemia in plasma, all at very
low levels (range 2.35e2.61 log IU/mL). None of these four women
had low (<200/mm3) CD4 counts (range 270e852), and all had
normal pregnancy outcomes, with no preterm delivery, low birth-
weight, birth defects, CMV or HIV transmission reported. Interest-
ingly, all the four mothers had detectable HIV in plasma at third
trimester (range 99e20 004 copies/mL).
This study showed that in a large cohort of pregnant women
with HIV, roughly two-thirds had positive serology for CMV, with
no adverse consequences of coinfection on the main pregnancy
outcomes. This rate is almost identical to that observed in two
different studies conducted among a general population of preg-
nant women in Northern and Southern Italy, who showed prev-
alences of positive CMV serology of 68.3% (1925/2817) and 65.9%
(595/797), respectively [5,6], suggesting similar CMV prevalence
for HIV-negative and HIV-positive pregnant women. It was also
shown in a nested evaluation that among pregnant women
with HIV with positive serology for CMV and no signs of primary
infection, a small proportion (4/123, 3.3%) have detectable CMV
DNAaemia, usually at low levels. This figure is consistent with
published data in an HIV-CMV coinfected African population, in
whom rate of detectable CMV in plasma was 4.8% (7/146) [7],
suggesting slightly higher rate of CMV DNAaemia among preg-
nant women with HIV compared with the general population.
In a previous Italian study on a general population of CMV IgG-
positive pregnant women with no evidence of primary infection,
0.5% (4/774) had positive, low-level CMV DNAaemia [8]. A similar
rate (2/134, 1.4%) was found in an unselected population of Turk-
ish pregnant women [9]. Detectable low-level CMV DNAaemia
could represent either subclinical viral reactivation or the termi-
nal phase of blood viral clearance after a recent primary infec-
tion. It is unknown whether partial immunosuppression in
pregnant women with HIV may be responsible for low-level
CMV replication and detectable DNAaemia, and it was not
possible to define timing of CMV infection by antibody avidity
testing or evaluation of CMV-specific IgM. In any case, asymp-
tomatic maternal CMV DNAaemia in a context of relatively pre-
served CD4 counts seems to represent for pregnant womenblished by Elsevier Ltd. All rights reserved.
Table 1
Characteristics and pregnancy outcomes according to CMV serostatus
Women’s characteristics CMV-positive CMV-negative CMV-positive CMV-negative p-valuea
N Median values (IQR)
Age, years (n: 2245) 1486 759 33 (29e36) 33 (28e37) 0.924
CD4 cell count, cells/mm3 (n: 1453)b 998 455 437 (297e591) 425 (289e612) 0.978
n/N % n/N %
At least one previous pregnancy (n: 2218) 1090/1467 74.3 551/751 73.4 0.636
History of AIDS-defining events (n: 2220) 84/1470 5.7 45/750 6.0 0.785
Antiretroviral-treatment experienced (n: 2185) 929/1447 64.2 504/738 68.3 0.057
On treatment at conception (n: 2225) 777/1475 52.7 390/750 52.0 0.762
Pregnancy outcomes ORc OR 95% CI
Miscarriage or fetal demise (n: 1941) 95/1313 7.2 56/628 8.9 0.797 0.564e1.125 0.196
Preterm delivery (n: 1672) 234/1152 20.3 108/520 20.8 0.972 0.753e1.256 0.830
Low birthweight (<2500 g) (n: 1576, twins included) 250/1082 23.1 101/494 20.4 1.169 0.901e1.517 0.239
Very low birthweight (<1500 g) (n: 1576, twins included) 37/1082 3.4 11/494 2.2 1.555 0.786e3.074 0.205
Small by gestational age (<10th percentile) (n: 1516, singletons only) 130/1034 12.6 53/482 11.0 1.164 0.829e1.634 0.381
Complications of deliveryd (n: 1606) 85/1100 7.7 37/506 7.3 1.062 0.711e1.586 0.771
Major birth defects (n: 1616) 39/1108 3.5 17/508 3.3 1.054 0.590e1.881 0.860
HIV transmission (n: 1235) 14/857 1.6 8/370 2.1 0.768 0.319e1.847 0.556
IQR, interquartile range; ARV, antiretroviral therapy.
a Mann-Whitney U test for quantitative variables and chi-square test for categorical variables.
b Second trimester.
c Reference category: CMV-positive.
d Usually represented by surgical wound infections and fever.
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